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Merkel cell carcinomaMerkel cell polyomavirus (MCPyV) is associated to Merkel cell carcinoma (MCC). We studied 113 MCC tu-
moral skin lesions originating from 97 patients. MCPyV detection was higher in fresh-frozen (FF) biopsies
(94%) than in formalin-ﬁxed parafﬁn-embedded biopsies (39–47%). Mean viral load in FF tumor was of 7.5
copies per cell with a very wide range (0.01–95.4). Nineteen complete sequences of LTAg were obtained,
mainly from FF biopsies when the viral load was high. Seventeen showed stop codons, all localized down-
stream of the pRb protein binding domain. Sequence comparison and phylogenetic analysis showed that
all sequences clustered in the large C clade of MCPyV strains. MCPyV integration was demonstrated in 19
out of 27 FF MCC DNA biopsies without evidence of speciﬁc host cellular genome integration site. In 13/19
cases, the viral junction was located within the second exon of the LTAg, after the pRB binding domain.
© 2012 Elsevier Inc. All rights reserved.Introduction
A new human polyomavirus has been recently identiﬁed, using
digital transcriptome subtraction method, in tumor tissues of patients
suffering from Merkel cell carcinoma (MCC) (Feng et al., 2008). This
rare cancer, an aggressive cutaneous neuroendocrine tumor occurring
mainly in elder patients, is associated with sun exposure, immuno-
suppression and a history of previous malignancy (Heath et al.,
2008; Hodgson, 2005). The original association between this ﬁfth dis-
covered (among a current total of nine) human polyomavirus, called
Merkel cell polyomavirus (MCPyV), and MCC tumors has been con-
ﬁrmed in several series of patients in the USA (Duncavage et al.,
2009, 2011; Garneski et al., 2009; Houben et al., 2010; Paulson et
al., 2010; Wu et al., 2010), Europe (Andres et al., 2010; Becker et al.,
2009; Fischer et al., 2010; Foulongne et al., 2008, 2009; Kassem ett Physiopathologie des Virus
, Institut Pasteur, 28 rue du Dr
x: +33 1 40 61 34 65.
rights reserved.al., 2008; Laude et al., 2010; Mangana et al., 2010; Sastre-Garau
et al., 2009; Schrama et al., 2011; Sihto et al., 2009; Touze et al.,
2009; Varga et al., 2009; Wieland and Kreuter, 2011), Australia
(Bialasiewicz et al., 2009; Paik et al., 2011) and Japan (Katano et al.,
2009; Kuwamoto et al., 2011; Nakamura et al., 2010).
Recent studies have demonstrated a relatively frequent presence
of such MCPyV in non-lesional skin DNA of patients with MCC but
also in the skin of persons with other cutaneous diseases and of
healthy individuals (Foulongne et al., 2009, 2010; Katano et al.,
2009; Mertz et al., 2011; Murakami et al., 2010; Pantulu et al., 2010;
Schowalter et al., 2010). This ﬁfth polyomavirus has also been
detected in tissues of the oral cavity and the respiratory tract as
well as blood (Babakir-Mina et al., 2010; Bergallo et al., 2010;
Bialasiewicz et al., 2009; Campello et al., 2011; Dang et al., 2011;
Goh et al., 2009; Kantola et al., 2009; Laude et al., 2010; Loyo et al.,
2010; Mertz et al., 2010; Pancaldi et al., 2011). Moreover, serological
studies have demonstrated a high seroprevalence of this virus in the
tested populations (Carter et al., 2009; Chen et al., 2010; Faust et al.,
2011; Kean et al., 2009; Pastrana et al., 2009; Paulson et al., 2010;
Schowalter et al., 2010; Tolstov et al., 2009; Touze et al., 2010,
2011). All together, these features indicate that, as most of the other
Table 1
Detection and viral load quantiﬁcation of MCPyV by PCR and qPCR.
Specimen MerkT LT3 qPCR: mean [range]
(copies per cell)
MCC fresh-frozen tumor 32/36 (88%) 34/36 (94%) 7.49a [0.01; 95.41]
135C. Martel-Jantin et al. / Virology 426 (2012) 134–142polyomaviruses present in humans, MCPyV seems highly prevalent in
the human population.
Concerning pathogenesis, MCPyV has been shown, by classical
Southern blot, to be clonally integrated into the tumor cells in a series
of 8 cases of MCC (Feng et al., 2008). Furthermore, while analyses of the
MCPyV sequences have revealed a very low genetic variability, a molecu-
lar signature, consisting ofmutationswhich truncate the potent oncopro-
tein large T (LT) antigen, has been remarkably observed in the MCPyV
present in the tumoral cells (Laude et al., 2010; Nakamura et al., 2010;
Shuda et al., 2008). This feature suppresses the helicase domain of LT an-
tigen which is required for viral replication (Houben et al., 2011a; Kwun
et al., 2009; Shuda et al., 2008). Most patients with MCC exhibited high
titers of serum antibodies directed against various MCPyV proteins
(Touze et al., 2011). Lastly, expression of the LT in MCC cells has been
demonstrated (Houben et al., 2010; Mogha et al., 2010; Nakamura et
al., 2010; Shuda et al., 2009). Thus, such data bring strong evidence for
a causal relationship between MCPyV and MCC. Only few studies have
speciﬁcally looked for the integration sites of MCPyV into MCC tumor
cells (Duncavage et al., 2011; Laude et al., 2010; Sastre-Garau et al., 2009).
Our goals were to:
1) Detect and quantify MCPyV in a large series of skin biopsies of MCC
tumors but also of Kaposi sarcoma (KS) and of non-lesional skin.
2) Get new insights into both the global genetic variability and the
speciﬁc mutations of the large T antigen gene and/or complete
MCPyV sequences.
3) Investigate the integration sites at the level of both the host and
the viral genome in MCC tumors.
Results
Patients
Westudied a series of 97 patientswithMerkel cell carcinoma. As seen
in Fig. 1, they were 37 men and 60 women with a mean age of 79 years
(range: 55 to 100). A total of 113 biopsies were obtained from these
patients including 36 fresh frozen tissues, from 30 primary tumors and
6 lymph-nodes, with in one case a couple of samples from the same
patient. The other 77 samples were formalin-ﬁxed parafﬁn (FFPE) and
include 66 primary skin lesions and 11 lymph-nodes. These 77 FFPE sam-
ples originated from only 68 patients. Furthermore, 7 samples were
available both as FFPE and fresh frozen biopsies. In 7 cases, two FFPE
biopsies originated from the same patient with one from the skin, the
other from the lymph-node. Lastly, in 2 cases, 2 samples from the skin
were available for a single patient. The other studied group included 21
fresh frozen skin biopsies of Kaposi sarcoma lesions, as well as 32 fresh
frozen biopsies of clinically normal skin. Lastly, we also studied peripher-
al blood from 8 patients with MCC and from 10 healthy individuals.
MCPyV detection and viral load quantiﬁcation
All the 113 DNA tested were ampliﬁed by the speciﬁc primers pair
for the human beta globin demonstrating integrity and ampliﬁability0%
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Fig. 1. Age distribution of the 97 patients with a diagnosis of Merkel Cell Carcinoma
analyzed for MCPyV detection in this study.of the DNA samples. Using LT3 andMerkT primers pairs, speciﬁc for two
different fragments of the second exon of the gene coding the LT anti-
gen, MCPyV sequences were detected respectively in 88 to 94% of the
36 DNAs from fresh-frozen MCC tumor tissues and only in 39 to 47%
of the FFPE tissues (Table 1). Considering all the results, LT3 PCR was
more efﬁcient than the MerkT one. This may be due to the presence of
a 3′-deletion in the LT antigen gene locus, that could include this region.
In the DNAs from the KS tissues and from the clinically normal
skin biopsies, the detection was less frequent than in the DNAs from
the frozen MCC tumors. Lastly, MCPyV was detected in the PBMCs
DNA of MCC patients in only 2 patients out of the 8 tested and in
only 1 healthy individual out of 10. Among the 9 FFPE sample pairs,
originating from the same patients, 8 couples were both positive
while in one case, the detection was only found in the skin but not
in the lymph-node. The only pair of the frozen samples was found
positive for both skin and lymph-node.
Quantiﬁcation assay of the viral load was performed in 27 cases of
DNA from fresh frozen tissues and on 23 DNAs from FFPE samples.
Viral load was more frequently detected in fresh frozen tissues
(24/27=89%) than in FFPE samples (15/23=65%). Furthermore, as
seen in Tables 1 and 2, the viral load level was higher in the MCC
fresh frozen biopsy DNAs (mean 7.49 copies per cell) than in the
FFPE ones (mean 3.01 copies per cell). However, it is worthwhile to
note the wide range of the viral load level in both series. The viral
load obtained in the other tissues (KS, normal skin, PBMC of MCC)
was very low or even not detectable.
Genetic variability and mutations in the gene coding the LT antigen in
patients with MCC
Several primer pairs were used to attempt ampliﬁcation of the
full-length LT antigen gene locus from DNA extracted from MCC tis-
sue tumors. The different amplicons were then directly sequenced.
Concerning the fresh frozen tissue DNA, in 18 cases out of 36, we suc-
ceeded to obtain the complete sequence (LT Ag 2885 bp) while in 14
cases, only partial sequences (from 893 bp to 1537 bp) were obtained
(Table 2). Concerning the 23 DNA from FFPE tissues, we succeeded to
get a complete sequence in only one case, while in 8 other cases, only
partial ones were obtained.
Concerning the fresh-frozen samples, the full-length LT antigen
gene locus sequence was obtained more frequently when the viral
load was higher than 5 copies per cell (7/10 cases—70% versus 4/13
cases—30%), and partial sequences were mainly obtained when the
viral load was below 5 copies per cell. In the four cases, in which
ampliﬁcation was negative, the qPCR was negative or very low (0.11
copies per cell) in two and one cases respectively while it was of 4.1
copies per cell in the last case.biopsies
MCC formalin-ﬁxed parafﬁn
embedded biopsies
36/77 (47%) 30/77 (39%) 3.01b [0.15; 16.65]
Fresh-frozen tumoral skin
biopsies (Kaposi sarcoma)
3/21 (14%) 11/21 (52%) 0.004c
Fresh-frozen healthy skin
biopsies (Kaposi sarcoma)
5/32 (16%) 26/32 (81%) 0.0006c
Buffy-coats (healthy individual) 1/10 (10%) 0 0.0003
Blood from patients with MCC 2/8 (25%) 0 0.0003
a Calculated on a total of 27 samples; 9 samples already quantiﬁed (Sastre-Garau et
al., 2009).
b Calculated on a total of 23 samples (all being positive for both MerkT and LT3
primer pairs).
c Calculated on a total of 12 samples (6 tumors and 6 healthy skin from the same
person respectively, all being positive for both MerkT and LT3 primer pairs).
Table 2
Summary of virological data (PCR and qPCR), sequence of LT Ag and presence of integration of MCPyV in 59 samples from MCC tumors.
Sample Age Sex LT3 MerkT qPCR (copies per cell) LT Aga Stop codonb Integration
FraMerk-1 76 M Yes Yes 4.60 2885 1505 Yes
FraMerk-2 71 F Yes Yes Neg 2885 1619 Yes
FraMerk-3 75 F Yes Yes 3.89 2885 1703 Yes
FraMerk-4 82 F Yes Yes 1.98 1537 No Yes
FraMerk-5 61 M Yes Yes 0.12 1526 1391 –
FraMerk-6 56 M Yes Yes 4.50 1537 No Yes
FraMerk-7 55 F Yes Yes 0.01 1537 1577 Yes
FraMerk-8 73 M Yes Yes 7.42 2885 1409 Yes
FraMerk-9 85 F Yes Yes 6.46 2885 1398 Yes
FraMerk-10 80 M Yes Yes 20.26 1432 No –
FraMerk-11 75 M – Yes 0.39 2885 2093 –
FraMerk-12 73 M Yes – 14.99 893 No Yes
FraMerk-13 73 M Yes – 4.10 – – –
FraMerk-14 66 F Yes Yes 3.13 1537 1409 –
FraMerk-15 79 M Yes Yes 4.19 1537 1391 Yes
FraMerk-16 55 M Yes – 6.90 893 No Yes
FraMerk-17 81 F Yes – 1.43 1202 No –
FraMerk-18 68 M – Yes Neg – – Yes
FraMerk-19 58 F Yes Yes 0.04 1202 No Yes
FraMerk-20 74 M Yes Yes 7.80 2885 1409 Yes
FraMerk-21 81 M Yes Yes 0.11 – – –
FraMerk-22 70 F Yes Yes 14.47 2885 1463 Yes
FraMerk-23 64 M Yes Yes 95.41 2885 1403 Yes
FraMerk-24 64 F Yes Yes 12.88 2885 1403 Yes
FraMerk-25 60 M Yes Yes 4.50 1432 No Yes
FraMerk-26 72 F Yes Yes 9.64 2885 1391 Yes
FraMerk-27 71 F Yes Yes Neg – – –
FraMerk-28 82 M Yes Yes Pub 1202 No Pub
FraMerk-29 72 M Yes Yes Pub 2885 1409 Pub
FraMerk-30 79 F Yes Yes Pub 2885 1391 Pub
FraMerk-31 81 M Yes Yes Pub 2885 1757 Pub
FraMerk-32 80 M Yes Yes Pub 2885 No Pub
FraMerk-33 82 F Yes Yes Pub 2885 1463 Pub
FraMerk-34 85 M Yes Yes Pub 2885 1598 Pub
FraMerk-35 63 M Yes Yes Pub 1500 1582 Pub
FraMerk-36 83 M Yes Yes Pub 2885 1562 Pub
FraMerk-37 75 F Yes Yes 6.93 1450 No –
FraMerk-38 75 F Yes Yes 9.90 1395 No –
FraMerk-39 92 F Yes Yes 16.65 1432 1403 –
FraMerk-40 76 F Yes Yes Neg 2885 No –
FraMerk-41 71 F Yes Yes 2.12 812 No –
FraMerk-42 70 M Yes Yes 2.32 1432 No –
FraMerk-43 55 M Yes Yes 3.37 1432 No –
FraMerk-44 82 F Yes Yes 1.36 1432 No –
FraMerk-45 71 M Yes Yes Neg 1432 1403 –
FraMerk-46 87 F Yes Yes 0.70 – – –
FraMerk-47 70 M Yes Yes 2.28 – – –
FraMerk-48 84 F Yes Yes 4.08 – – –
FraMerk-49 97 M Yes Yes 0.16 – – –
FraMerk-50 84 F Yes Yes 3.87 – – –
FraMerk-51 71 M Yes Yes 4.84 – – –
FraMerk-52 94 F Yes Yes 14.75 – – –
FraMerk-53 66 F Yes Yes Neg – – –
FraMerk-54 79 M Yes Yes Neg – – –
FraMerk-55 69 F Yes Yes Neg – – –
FraMerk-56 80 M Yes Yes Neg – – –
FraMerk-57 63 M Yes Yes Neg – – –
FraMerk-58 82 F Yes Yes Neg – – –
FraMerk-59 91 F Yes Yes 2.0 – – –
FraMerk 1–36: samples of fresh frozen biopsies; FraMerk 37–59: samples of formaldehyde-ﬁxed parafﬁn-embedded biopsies.
–: not detected.
Pub: published (Sastre-Garau et al., 2009).
a Fragment detected for the LT antigen gene locus for which a sequence (total or partial) was obtained.
b Position of the stop codons according to the numeration (Shuda et al., 2008).
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were not identical among them. We can thus consider that each
MCC tumor harbor a speciﬁc strain of MCPyV, deﬁned mostly by sin-
gle nucleotide polymorphisms. However, the viral inter-strain genetic
variability was very low. Indeed, all the sequences were very closely
related to themselves exhibiting more than 97.2% of nucleotidic
similarity in their compared fragments respectively (from 893 bp
to 2885 bp). Furthermore, they displayed >98% identity with the 4available prototype strains obtained from MCC tumors: MCC339
(EU375804.1); MCC350 (EU375803.1); MCVw156 (HM355825); MKL-1
(FJ173815.1).
When we analyzed more precisely the observed mutations, com-
parison of the 41 new complete/partial sequences between them
indicated the presence of different single nucleotide polymorphisms.
Indeed, 36 out of the 41 sequences presented at least 1 silent muta-
tion. Among them, 20 sequences presented between 2 and 12 silent
137C. Martel-Jantin et al. / Virology 426 (2012) 134–142mutations, and 2 sequences harbored 21 and 22 silent mutations.
Furthermore, 28 out of the 41 sequences exhibited from 1 to 8 non-
synonymous mutations. Lastly, 3 sequences presented between 1
and 4 deletions of one nucleotide and 3 exhibited between 1 and 3
insertions of one nucleotide. Moreover, 8 sequences showed a dele-
tion of 4, 10, 24, 34, 39, 72, and 139 nucleotides respectively and 1
sequence showed an insertion of 9 nucleotides when compared
with the reference sequence of the MCVw156, whose LT Ag is not
truncated (HM355825).
For 3 patients, for whom we had both tumor and lymph-node
FFPE samples, we could obtain only short fragments of 308 bp (PCR
LT3) and 404 bp (PCR MerkT). As expected, we could verify that
sequences from primary skin tumor and lymph-node metastasis
exhibited 100% identity.
A full-length sequence of MCPyV was obtained in 4 cases (FraMerk-
2, -20, -22, -24) in MCC tumor tissue DNA, suggesting that they might
originate from an episomal form.
MCC molecular signature
Among 17 out of 19 new complete sequences of the full-length LT
antigen gene locus, we found different mutations leading to a truncat-
ed form (presence of stop codon) of the LT Ag. They consisted in:
i) single substitution in 10 cases, or: ii) a frameshift, which generated
a stop codon, due to a deletion (5 cases) or an insertion (2 cases). The
mutations causing the stop codon were always localized after the pRb
ﬁxation domain and all leaded to lack of expression of the helicase
domain.
In the two remaining cases (one from a fresh frozen tissue DNA,
the last one from a FFPE sample), the full-length sequences of LT Ag
encoded a non-truncated protein. Interestingly, among these, one0.001
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Fig. 2. Phylogenetic tree generated with the Neighbor-Joining method on 31 sequences of
different origin of the isolates: C as Caucasian and A as Asian. The 4 new sequences genera(FraMerk-32) presented an integrated form with a viral junction in
the LT Ag thus indicating an interruption of this gene (Sastre-Garau
et al., 2009). Integration was not detected for the second sample,
most likely due to the poor quality of DNA.Phylogenetic analyses of MCPyV strains
A ﬁrst phylogenetic study was performed with the Neighbor-
Joining (NJ) method on the whole sequence of the MCPyV, including
the 4 new complete sequences obtained in the present study and 27
other MCPyV strains available in GenBank. As seen in Fig. 2, this anal-
ysis performed on 31 strains clearly indicated the presence of two
main clades, highly phylogenetically supported. We proposed to
label provisionally these 2 clades A and C (Fig. 2). The four new
sequences obtained in our work belonged to the C clade. Further-
more, analysis showed a “star like tree” for the MCPyV strains of the
C clade, strongly suggesting a common origin for these strains with
a possible founder effect (Fig. 2). With the exception of sequence
MCC350, the sequences of the clade C are more closely related to
themselves than to the strains of the clade A. Indeed, the inter-
strain variability of clade C sequences is lower than those of the
clade A (1.98–4.5%; 0.3–1.6% respectively).
A second phylogenetic analysis on the full-length LT antigen gene
locus, including 19 new sequences generated in this study, all origi-
nating from French patients of Caucasian background, and 39 strains
available in GenBank, showed also the presence of 2 main clades (A
and C), despite lower bootstrap values (Figure S2).
Whatever the sequence of the genome analyzed (partial vs com-
plete), 4 sequences (MCV16b, MCV10b, MCV25b and TKS) (Katano
et al., 2009; Schowalter et al., 2010) are comprised in any case inMCV16b
TKS
MCV10b
MCV25b
4b 
4a
100
96
A
MCPyV complete genome. We tentatively propose the following nomenclature for the
ted in this study are in bold. They all originate from French Caucasian patients.
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Fig. 3. Integration sites of MCPyV in MCC tumoral tissues: (A) in the cellular genome
and (B) in the viral genome.
138 C. Martel-Jantin et al. / Virology 426 (2012) 134–142the clade A. These 4 sequences are originated from persons of Asian
background.
Integration of MCPyV in MCC tumoral tissues
Using the DIPS-PCR method, we could demonstrate the integra-
tion of MCPyV in 19 cases of the newly tested 27 DNA samples origi-
nating from fresh frozen biopsies of tumoral MCC. However, we did
not succeed to demonstrate any integration by using 23 DNAs from
FFPE biopsies. For all cases, presence of both 5′ and 3′ host-virus junc-
tions was analyzed and a score was assigned following DIPS-PCR and
bioinformatic analysis. Interestingly, among the 19 positive cases, 3′
junction was much more frequently observed (15/19, 79%) than 5′
junction (4/19, 21%). Moreover, we were not able to simultaneously
detect both junctions in a same case. Concerning the patient's cellular
genome, the virus-host junctions were found on 9 different chromo-
somes (Table 3 and Fig. 3A). The most frequent localization (21%=
4/19 cases) was on chromosome 5. Each integration site was unique
among the studied ones. However, in two cases we could not precise-
ly determine it, since it was observed in conserved regions of the cel-
lular genome. Concerning the viral genome, the break points occurred
mainly (68%=13/19 cases) into the second exon of the LT Ag with
none being on the same site (Fig. 3B). Interestingly, among all the dif-
ferent cellular genes involved in the integration process, some are di-
rectly implicated in carcinogenesis, such as X-ray repair
complementing defective repair in Chinese hamster cells 4 (XRCC4)
and phospholipase A2, group IVA (PLA2G4A) genes (Gomes et al.,
2010; Tosato et al., 2010).
Discussion
The results of our study raise some questions and comments
concerning MCPyV, its physiopathology, its relationship with MCC
and its genetic variability.
1) Detection of this new polyomavirus and its viral load in MCC
tumor
Numerous studies, after the pioneer work of Chang and Moore
(Feng et al., 2008) have conﬁrmed the detection of MCPyV in theTable 3
Integration analysis of MCPyV in MCC: virus-cell junctions in 19 cases.
Sample Viral junction Cellular
junction
Gene Distance (bp)
FraMerk-1 5′–4698 (VP2–VP3) 5q14.2 XRCC4 131,805
FraMerk-2 4162 (VP1)–3′ 4p15.2 KCNIP4 /
FraMerk-3 5′–2049 (LT Ag) 19p13.2 EVI5L /
FraMerk-4 2210 (LT Ag)–3′ 4p14 RELL1 60,724
FraMerk-6 2414 (LT Ag)–3′ 1q31.1 PLA2G4A 247,984
FraMerk-7 2173 (LT Ag)–3′ a n.d n.d
FraMerk-8b 4626 (VP2–VP3)–3′ 6q24.1 MAP3K7IP2 8,443,561
FraMerk-9 2585 (LT Ag)–3′ 19q13.2 ECH1 /
FraMerk-12 1399 (LT Ag)–3′ 5q11.2 ISL1 251,753
FraMerk-15 2597 (LT Ag)–3′ 5q11.2 ISL1 538,333
FraMerk-16 2258 (LT Ag)–3′ 1q25.1 RABGAP1L /
FraMerk-18 5′–510 (ST Ag) a n.d n.d
FraMerk-19 3269 (VP1)–3′ 3q21.3 EEFSEC /
FraMerk-20 1187 (LT Ag)–3′ 18q12.1 CDH2 237,768
FraMerk-22 5′–3527 (VP1) 6p22.3 CDKAL1 /
FraMerk-23 1461 (LT Ag)–3′ 14q12 NOVA1 483,848
FraMerk-24c 2091 (LT Ag)–3′ 1p22.3 MCOLN2 /
FraMerk-26 1321 (LT Ag)–3′ 4q22.2 GRID2 /
FraMerk-27 999 (LT Ag)–3′ 5p13.2 PRLR /
/: integration in the gene.
n.d.: not determined.
a Integration in a conserved region.
b 11 nucleotides not identiﬁed between the viral/cellular junction.
c 16 nucleotides not identiﬁed between the viral/cellular junction; in addition to the
viral sequence described, another sequence (81% identity with MCC350) was observed
downstream the cellular sequence.majority of the tested MCC tumors (Andres et al., 2010; Becker et
al., 2009; Bhatia et al., 2010; Bialasiewicz et al., 2009; Dang et al.,
2011; Duncavage et al., 2009, 2011; Fischer et al., 2010;
Foulongne et al., 2008, 2009; Foulongne et al., 2010; Garneski
et al., 2009; Houben et al., 2010; Kassem et al., 2008; Katano
et al., 2009; Koljonen et al., 2009; Kuwamoto et al., 2011; Laude
et al., 2010; Mangana et al., 2010; Nakamura et al., 2010; Paik et
al., 2011; Paulson et al., 2010; Reisinger et al., 2010; Sastre-Garau
et al., 2009; Schrama et al., 2011; Sihto et al., 2009; Touze et al.,
2009; Varga et al., 2009; Wieland and Kreuter, 2011; Wu et al.,
2010). Indeed, by PCR based methods, several authors have
detected this virus in a large proportion of MCC tumoral samples,
regardless of the origin (US, Europe, Australia) and risk factors of
the patients. Furthermore, and as clearly seen in our studies, the
detection rate was always higher in DNA extracted from fresh or
frozen tumor samples that in DNA from FFPE tissues (Foulongne
et al., 2008, 2009; Laude et al., 2010; Touze et al., 2009). This is,
of course, very likely linked to an important degradation of the
DNA in ﬁxed tissue making PCR less sensitive. However, in most
studies performed on relatively large series, around 10 to 20% of
the samples from MCC tumors are found negative for MCPyV
detection using several speciﬁc primers (Becker et al., 2009;
Duncavage et al., 2009; Feng et al., 2008; Foulongne et al., 2008;
Kassem et al., 2008; Touze et al., 2009; Varga et al., 2009). This is
also well exempliﬁed by the initial study by Chang and Moore,
who did not ﬁnd any trace of MCPyV in 2 cases out of the 10 of
their series despite a search using a wide range of primer pairs
(Feng et al., 2008). Even if some different technical aspects (quality
of the DNA, sensibilities of the PCR methods,…) could not be ruled
out in some of the cases, such ﬁndings also indicate the possibility
that some MCC could not be associated with MCPyV. Such a
hypothesis thus raises, as already suggested, the possible heteroge-
neity of the MCC cancer with a speciﬁc subset causally associated
with MCPyV and another more rare MCC, very similar on a patho-
logical point of view, but probably not related to MCPyV (Feng et
al., 2008; Kuwamoto et al., 2011; Schrama et al., 2011). Several
other features argue for such a possibility. Interestingly, patients
with MCC associated with MCPyV infection have a better outcome
thanMCC patientswithout detectable levels ofMCPyVDNA (Laude
et al., 2010; Paulson et al., 2011; Touze et al., 2011). Furthermore,
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strong immune response function, as shown by levels of serum
antibodies directed against VP1 proteins (Touze et al., 2011) and
level of CD8 inﬁltration in the tumor (Paulson et al., 2011), corre-
late with better outcomes for patients with MCC (Buck and Lowy,
2011).
Another important ﬁnding, pointed out by several studies and
conﬁrmed here on large series, is that a certain proportion of
MCC tumors positive for MCPyV detection carry less than one
copy of the viral genome per tumor cell (Buck and Lowy, 2011;
Foulongne et al., 2009; Garneski et al., 2009; Katano et al., 2009;
Laude et al., 2010; Sastre-Garau et al., 2009). Depending on the
studies, this substantial fraction varies from 10% to 100% and
reaches 29% in our study. One interpretation for such a quite unex-
pected ﬁnding for a viral-induced tumor is, as suggested above,
that some MCC may not causally be related to MCPyV infection
but are linked to another cause yet to be determined (Buck and
Lowy, 2011). Another interesting but more speculative possibility,
raised in a recent paper (Touze et al., 2011), is the classical hit-and-
runmechanism (Houben et al., 2011b; Niller et al., 2011). However,
in contrast to the situation found in some rare animal carcinogenesis
models, such a possibility has not yet been clearly demonstrated in
human cancer (Buck and Lowy, 2011).
2) Genetic variability of MCPyV
Sequence comparison of the 19 new full-length LT antigen gene
locus and of the 4 new complete MCPyV sequences indicates a
very low genetic divergence among themselves, as well as with
the classical MCPyV prototypes from MCC tumors but also with
most of the other complete viral sequences originating from
healthy persons. This conﬁrms clearly the great in vivo genetic sta-
bility of this human polyomavirus. It is however worthwhile to
note that, to our knowledge, most of the MCPyV sequences yet
available, including those generated in this study, were detected
in patients living in Europe (mainly France), or of European ances-
try (USA, Australia) while very few data are known concerning the
situation of the virus in other geographical areas.
Despite such apparent great genetic stability, phylogenetic analy-
sis, performed by the NJ method and using all the MCPyV com-
plete genome sequences, clearly indicate the presence of two
clades highly supported by high boostrap values (Fig. 2). The
four new sequences were comprised in clade C, the largest one.
Indeed, clade C comprises most of the available sequences including
those from French Caucasian patients from our series. Interestingly,
concerning the phylogenetic tree of the whole genomes, and, as
recently discussed by Schowalter et al., 3 out of the 4 sequences orig-
inated from patients born in Asia, 10b, 16b, 25b (Schowalter et al.,
2010), and the sequence TKS (Katano et al., 2009), originated from
a Japanese patient, were located in clade A. Thus, we propose to
label these two clades A for Asian and C for Caucasian. However,
results of ongoing studies, including analysis of viruses from healthy
persons of different geographical origins, will be necessary to con-
ﬁrm such data on a larger scale.
Such very preliminary results, to be conﬁrmed on largest series of
strains originating from different geographical areas, may however
suggest the possibility of geographically related genotypes of
MCPyV. This would be reminiscent of the situation found for JC
and BK viruses (Luo et al., 2008; Wirth et al., 2005; Zhong et al.,
2007). Indeed, in these other human polyomaviruses, especially for
JC, different viral genotypes, each of them linked to a speciﬁc geo-
graphical origin, have been described (Guo et al., 1998; Yogo et al.,
2004). Furthermore, several investigations have demonstrated the
use of such genotypes as a tracer for human population migrations
(Wirth et al., 2005; Yogo et al., 2004).
3) Variability of T antigen coding region and presence of stop codon
In this work, by studying DNA extracted from MCC tumors, we
found, among 17 out of 19 complete sequences of the full-lengthLT antigen gene locus, the presence of different mutations leading
to a predicted truncated form (presence of stop codon) of the LT
Ag. Such ﬁndings strengthen previous work, pioneered by Shuda
et al., who demonstrated that nine MCC tumor derived LT Ag
genomic sequences harbor mutations prematurely truncating the
MCPyV helicase (Shuda et al., 2008). In contrast, in their work, four
presumed episomal viruses from non-tumor source did not possess
this antigen signature mutation. Similar data were reported also
recently by Laude et al., who observed such molecular signatures
truncating MCPyV LT Ag in 8/12 MCC cases but not in respiratory
and urinary samples from 15 patients (Laude et al., 2010). Interest-
ingly, in two MCC tumor cases, we did not ﬁnd any truncation of
the LT Ag. Moreover, in one of the two, our study revealed an inte-
gration form with a viral junction in the LT Ag. This suggests the
co-existence, in the DNA of MCC tumor biopsy, of both episomal
form and truncated integrated form of MCPyV. This conﬁrms similar
results reported recently by Laude et al. (2010), in MCC tumors
DNAs. Interestingly, Foulongne et al. (2010), did not observe such
truncated form of the complete LT Ag sequence in two MCC tumors
as well as in 6 non-tumoral samples. They suggested that truncated
formmight however exist in MCC tumor DNA but as a minor subset
not ampliﬁed in their population-based sequencing approach used.
However, co-existence of viral integration, as shown above, may
also be a possibility not studied in their report.
In this work, we also obtained four complete sequences of the viral
genome from MCC tumor DNA. Interestingly, the ability to clone
full-length MCPyV genomes can also be due to the presence of inte-
grated viral DNA in the form of a series of tandem repeats of the viral
genome. This has been already well shown for both papilloma and
polyoma-induced tumors (Baker et al., 1987; Blanck et al., 1988;
Choo et al., 1988; Mendelsohn et al., 1982; Yiu et al., 1990). Surpris-
ingly, in all four cases, stop codons, leading to the truncation of the
LT Ag, were found in the genome. At present, only six other full-
length MCPyV genomes have been reported from MCC tumor
lesions (Feng et al., 2008, 2011) and one from a Kaposi sarcoma
tumor sample (Katano et al., 2009). Of these, 5 out of 6 MCC
genomes but also the KS one, carry truncating mutations in the LT
Ag. This raises the question of how a presumed episomal form
with such a stop codon could replicate and suggest the presence of
a minor subset of complete non-truncated strain as discussed
above. Another still hypothetic alternative would be the possibility
of complementation of such gene by homologs of related variant
viruses. Indeed, a large variety of related polyomaviruses have
been detected very recently on the human skin by several groups
(Schowalter et al., 2010; van der Meijden et al., 2010). Interestingly,
Schowalter et al. recently reported 17 complete MCPyV sequences
obtained from normal skin sample from healthy persons and most
of these MCPyV isolates encodes full-length open reading frame
for predicted MCV proteins including the LT Ag (Schowalter et al.,
2010).
Patientswith chronic lymphocytic leukemia (CLL) have a high risk of
MCC (Koljonen et al., 2009). Interestingly, Pantulu et al., reported
recently that 19/70 of CLL were infected by MCPyV (Pantulu et al.,
2010). Furthermore, mutational analyses revealed, in 6 among 19
MCPyV positive CLL, a novel 246 bp LT Ag deletionwhich terminates
the open reading frame leading to a loss of the helicase domain and
thus viral replication deﬁciency. Lastly, they also observed concom-
itantly mutated and wild-typeMCPyV in two cases of CLL DNA. This
might indicate, as suggested above in the case of MCC tumors, a
functional substitution by the MCPyV wild-type helicase (Pantulu
et al., 2010).
4) Integration of the MCPyV
Integration of the virus in the cellular genome could be demonstrat-
ed by DIPS-PCR in 19 cases. The quality of the DNA has shown to be
critical for this analysis, since the assay was valid only with fresh-
frozen, rather than FFPE biopsies. Results indicated that no speciﬁc
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cellular genome (Tables 2–3). In our study, 13 out of the 19 viral
junctions are located in the LT Ag region; this might be due to the
fact that this region constitutes more than 50% of the entire viral
genome (2885 out of 5387 bp). However, it is important to under-
line that, in all cases, the integration site is localized after pRb in
the second exon of the LT Ag. This conﬁrms, on a larger series, the
previous studies (Laude et al., 2010; Sastre-Garau et al., 2009), in
which 6 MCPyV out of 10 and 3 out of 6 cases respectively were
shown to be integrated at the 3′ end of the LT Ag. We can suppose
that a break in the MCPyV genome at the level of LT Ag could have
an equivalent role of a stop codon and thus lead to loss of helicase
expression and to inhibition of viral replication (Houben et al.,
2011a; Kwun et al., 2009; Shuda et al., 2008). Considering all our
results on the analysis of LT Ag gene locus, the coexistence of both
the full-length and truncated forms is in line with the presence of
more than one copy of MCPyV genome in the tumor. Furthermore,
one LT Ag gene might originate from the tumor cellular DNA and
the other from the peripheral blood cells DNA present in the small
vessels of the tumor.
Concerning the samples for which integration occurs in a region
other than the LT Ag gene locus, we can suppose that the lack of
viral replication might be rather due to a defective origin of replica-
tion as recently suggested (Kwun et al., 2009).
Regarding the host junction, chromosome5was frequently detected
but the precise locus was always different (Fig. 3). In two cases, integra-
tion occurred near two cellular genes XRCC4 and PLA2G4A, indicating
a possible implication in MCC that may be worthy to be furtherly
investigated.
Materials and methods
Subjects and samples collection
A multicentric collaboration between dermatology and pathology
departments in France (mostly Paris area) allowed us to obtain a series
of fresh frozen and/or formalin-ﬁxed parafﬁn-embedded (FFPE) biop-
sies and blood samples fromMCC.Moreover, two series of skin biopsies,
both tumoral and healthy, were obtained from patients with Kaposi
sarcoma (KS) in Maroc and Central African Republic (Duprez et al.,
2005, 2006). Patients provided an informed written consent prior to
the study.
DNA extraction
High molecular weight DNA was extracted from either fresh-
frozen and FFPE biopsies or peripheral blood mononuclear cells
(PBMC) using QIAamP DNAmini kit® and QIAamp Blood minikit®
(Qiagen, Hilden, Germany) respectively. All samples were deter-
mined to contain ampliﬁable DNA after being tested by polymerase
chain reaction (PCR) with the human beta-globin primers as previ-
ously described (Lo et al., 1989).
MCPyV detection and quantiﬁcation
Standard PCRwas performed using one previously and one in-house
designed primers pairs (Table S1-A, Figure S1) amplifying the genomic
fragment of T antigen coding region, with 500 ng of genomic DNA and
Hotstart DNA polymerase (Qiagen). Ampliﬁcation was performed for
45 cycles (94 °C for 45 s; annealing at 54 °C for MerkT/60 °C for LT3
for 30 s; 72 °C for 45 s) with a ﬁnal extension of 72 °C for 10 min. DNA
from known MCPyV positive MCC cases were used as positive controls.
PCR products were detected by agarose gel electrophoresis following
ethidium bromide staining.MCPyV DNA loads were quantiﬁed in duplicate by real-time PCR
using 40–100 ng of genomic DNA in a total volume of 20 μl by using
10× SYBR Green Mastermix (Qiagen) and speciﬁc primers sets for the
small t antigen (ST Ag) and IC5 housekeeping gene as previously
described (Sastre-Garau et al., 2009). Real-time PCR was carried out
on an Eppendorf Realplex instrument (Eppendorf AG, Barkhausenweg
1, 22339 Hamburg, Germany) and Ct values were calculated automati-
cally.ΔΔCtmethodwas used to calculate the viral copy number per cell
(Sastre-Garau et al., 2009).
MCPyV full-length T antigen locus sequence
In addition to the described samples used during all this study, nine
fresh-frozen biopsies (Sastre-Garau et al., 2009) were also included for
the analysis ofMCPyV full-length LT antigen locus (LT Ag). Entire or par-
tial fragments of the T antigen were obtained by PCR using a different
combination of primers (see Table S1-B). The entire ampliﬁed products
of the appropriate size (2900 bp) or the partial fragments were
sequenced using 18 different primers sets (Table S1-B) at Euroﬁns
MWG (Ebersberg, Germany).Multiple nucleotide and amino acid align-
ments were performed with the Clustal W algorithm implemented
in MacVector 9.0 (Mac Vector Inc., Cary, United States) or CLC DNA
Workbench 5 software (Aarhus, Denmark).
MCPyV complete genome ampliﬁcation
The complete viral genome corresponding to a 5387 bp fragment,
was obtained by using only one primer pair (CG Forward: 5′-
GCAAACTCCTTCTGCATATAGAC-3′; CG Reverse: 5′-AGAAACAGCA-
GAGGAGCAAATG-3′) and with 100 ng of each DNA sample (Figure
S1). A total of 40 cycles (92 °C for 10 s, 62 °C for 30 s, and 68 °C for
5 min 30 s) was performed, using 200 U of Expand 20 kbplus PCR
System dNTPack (Roche Applied Science, Basel, Switzerland), before a
ﬁnal extension of 7 min at 68 °C. The ampliﬁed DNA products were
puriﬁed on an agarose gel, cloned in the TOPO XL PCR Cloning Kit
(Invitrogen, Carlsbad, United States) and then sequenced (Euroﬁns
MWG) by using different primers sets (Table S1-C). Sequences were
veriﬁed on both DNA strands and analyzed as described above.
Phylogenetic analysis
Unrooted phylogenetic trees were generated by the NJ method,
with 31 sequences of MCPyV complete genome and 58 sequences of
full-length T antigen gene locus, performed in the PAUP program ver-
sion 4.0b10 (Sinauer Associates, Sunderland, MA, USA). The strains
were aligned with the DAMBE program version 4.2.13 and the ﬁnal
alignment was submitted to the Modeltest program version 3.6. The
General time-reversible (GTR) model was selected for both analyses.
The reliability of the inferred trees was evaluated by bootstrap analy-
sis on 1000 replicates, and numbers on each node indicate the
percentage of bootstrap samples (1000) in which the cluster is sup-
ported. Branch lengths are drawn to scale, with the bar indicating
0.001-nt replacement per site. The four new MCV complete sequences
(GenBank accession numbers: JN383838–JN383841) and the 19 full-
length T antigen locus sequences (GenBank accession numbers:
JN383823–JN383837)were analyzedwith 27 and 39 available sequences
respectively from the GenBank database.
Analysis of MCPyV integration
The integration sites of MCPyV in MCC were studied using the
DIPS-PCR technique (detection of integrated papilloma sequences),
which allowed the ampliﬁcation of the junctions comprised between
viral and cellular genomes. Brieﬂy, after tumor DNA digestion with a
restriction enzyme, the DNA fragments obtained were ligated to a
speciﬁc adapter and subjected to PCR ampliﬁcation using viral
141C. Martel-Jantin et al. / Virology 426 (2012) 134–142and adapter speciﬁc primers (Laude et al., 2010; Luft et al., 2001;
Sastre-Garau et al., 2009). The PCR products were excised from the
agarose gel and DNA was puriﬁed using MiniElute gel extraction kit
(Qiagen) and then sequenced (Euroﬁns MWG).
Finally, integration sites were determined by submitting sequences
to the following databases: UCSC Genome Browser assembly Feb 2009
(University of California, Santa Cruz, United States) and BLASTN. For
host-junctions analysis, only results with high alignment scores
(above 50) were considered as signiﬁcant and taken into account for
our analysis.
Supplementary materials related to this article can be found
online at doi:10.1016/j.virol.2012.01.018
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